By staff writers

February 24, 2012 -- Ultrasound contrast developer Acusphere has secured $2.5 million in new debt financing.

The company currently is conducting a special protocol assessment with the U.S. Food and Drug Administration (FDA) for a phase III study of its Imagify ultrasound contrast agent.

The study will compare stress ultrasound with Imagify to unenhanced stress ultrasound for detecting coronary artery disease.

Copyright © 2012

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking